Stoke Therapeutics Inc (NAS:STOK)
$ 13.9 -0.13 (-0.93%) Market Cap: 724.47 Mil Enterprise Value: 548.10 Mil PE Ratio: 0 PB Ratio: 4.61 GF Score: 38/100

Stoke Therapeutics Inc To Present Interim Data From MONARCH Study In Dravet Syndrome Interim Analysis Call Transcript

Sep 21, 2021 / 12:30PM GMT
Release Date Price: $25 (+5.71%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to Stoke Therapeutics MONARCH Study and Dravet Syndrome Interim Analysis. (Operator Instructions) I will now return the call over to your host. Eric Rojas. You may begin.

Eric Rojas
Stoke Therapeutics - VP, Head of IR

Thank you, Kevin and good morning. This is Eric Rojas, Head of Investor Relations with Stoke Therapeutics. On today's call, we will discuss results from the interim analysis of the Phase 1/2a clinical study of our investigational medicine STK-001 for the treatment of Dravet syndrome. Our speakers today is Dr. Edward Kaye, Stoke's CEO, and Dr. Barry Ticho, Stoke's Chief Medical Officer.

As you listen to this call, we recommend that you access the webcast slides and the investors section on our website. This call is being recorded and a replay will also be available on the Stoke website later today. We will make forward-looking statements on this call that is subject to the risks and uncertainties discussed in detail in today's press release, and then our filings with the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot